IMPACT BIOMEDICAL INC. 10-K

ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA Financial Statements IMPACT BIOMEDICAL INC TABLE OF CONTENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID: 606 ) 27 Consolidated Financial Statements: Consolidated Balance Sheets 28 Consolidated Statements of Operations 29 Consolidated Statements of Cash Flows 30 Consolidated Statements of Changes in Stockholders’ Equity 31 Notes to the Consolidated Financial Statements 32 26 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of Impact Biomedical, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Impact Biomedical, Inc., and its subsidiaries (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, changes in stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt Regarding the Company’s Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 2 to the financial statements, the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. Management’s plans in regard to these matters are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter. Basis for Opinion These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. GRASSI & CO., CPAs, P.C. We have served as the Company’s auditor since 2022. Jericho, New York March 28, 2025 27 I mpact BioMedical, Inc. and Subsidiaries Consolidated Balance Sheets As of December 31, 2024 2023 ASSETS Current assets: Cash and cash equivalents $ 1,999,000 $ 1,000 Other receivables - 128,000 Current portion of notes receivable 184,000 203,000 Prepaid expenses and other current assets 265,000 - Total current assets 2,448,000 332,000 Property, plant and equipment, net 17,000 287,000 Notes receivable 17,000 - Goodwill - 25,093,000 Other intangible assets, net 17,808,000 18,921,000 Total assets $ 20,290,000 $ 44,633,000 LIABILITIES AND STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 713,000 $ 832,000 Accrued expenses 194,000 230,000 Note payable, related party 8,878,000 12,074,000 Total current liabilities 9,785,000 13,136,000 Deferred tax liability, net 3,268,000 3,235,000 Total liabilities 13,053,000 16,371,000 Commitments and contingencies (Note 12) - - Stockholders’ equity Preferred stock, $ .001 par value; 100,000,000 shares authorized, 60,496,041 shares issued and outstanding ( 60,496,041 on December 31, 2023); Liquidation value $ 0.001 per share, $ 60,000 aggregate. $ 60,000 on December 31, 2023). 60,000 60,000 Common stock, $ .001 par value; 4,000,000,000 shares authorized, 11,503,955 shares issued and outstanding ( 10,000,000 on December 31, 2023) 11,000 10,000 Additional paid-in capital 41,857,000 38,113,000 Accumulated deficit ( 37,669,000 ) ( 12,961,000 ) Total stockholders’ equity of the Company 4,259,000 25,222,000 Non-controlling interest in subsidiaries 2,978,000 3,040,000 Total stockholders’ equity 7,237,000 28,262,000 Total liabilities and stockholders’ equity $ 20,290,000 $ 44,633,000 See accompanying notes. 28 I mpact BioMedical, Inc. and Subsidiaries Consolidated Statements of Operations For the Years Ended December 31, 2024 2023 2024 2023 Costs and expenses: Sales, general and administrative compensation (inclusive of stock based compensation) $ 718,000 $ 315,000 Sales and marketing 633,000 65,000 Professional Fees 446,000 724,000 Research and development 278,000 1,685,000 Depreciation and Amortization 1,119,000 1,120,000 Rent and utilities 32,000 - Impairment of fixed assets 263,000 - Impairment of goodwill 25,093,000 - Other operating expenses 171,000 119,000 Total costs and expenses 28,753,000 4,028,000 Operating loss ( 28,753,000 ) ( 4,028,000 ) Other income (expense): Interest income 13,000 13,000 Other income - 52,000 Change in fair value of note payable, related party 5,068,000 - Interest expense ( 1,065,000 ) ( 444,000 ) Loss from operations before income taxes ( 24,737,000 ) ( 4,407,000 ) Income tax expense ( 33,000 ) - Net loss $ ( 24,770,000 ) $ ( 4,407,000 ) Loss from operations attributed to noncontrolling interest 62,000 71,000 Net income (loss) attributable to common stockholders $ ( 24,708,000 ) $ ( 4,336,000 ) Earnings (loss) per common share: Basic $ ( 2.30 ) $ ( 0.07 ) Diluted $ ( 2.30 ) $ ( 0.07 ) Shares used earnings (loss) per common share: Basic 10,757,147 60,248,078 Diluted 10,757,147 60,248,078 See accompanying notes. 29 I mpact BioMedical, Inc. and Subsidiaries Consolidated Statements of Cash Flows For the Years Ended December 31, 2024 2023 Cash flows from operating activities: Net loss $ ( 24,770,000 ) $ ( 4,407,000 ) Adjustments to reconcile net loss to net cash used by operating activities: Depreciation and amortization 1,119,000 1,120,000 Stock based compensation 19,000 - Change in fair value of note payable, related party ( 5,068,000 ) - Change in deferred tax liability 33,000 - Impairment of fixed assets 263,000 - Impairment of goodwill 25,093,000 Decrease (increase) in assets: Other receivable 128,000 ( 128,000 ) Prepaid expenses and other current assets ( 265,000 ) 104,000 Increase (decrease) in liabilities: Accounts payable ( 436,000 ) 293,000 Accrued expenses ( 35,000 ) 167,000 Net cash used by operating activities ( 3,919,000 ) ( 2,851,000 ) Cash flows from investing activities: Purchase of property, plant and equipment - ( 18,000 ) Payments received on notes receivable 2,000 3,000 Net cash provided (used) by investing activities 2,000 ( 15,000 ) Cash flows from financing activities: Borrowings from revolving lines of credit, net 2,189,000 2,865,000 Issuances of common stock, net of issuance costs 3,726,000 - Net cash provided by financing activities 5,915,000 2,865,000 Net increase (decrease) in cash 1,998,000 ( 1,000 ) Cash and cash equivalents at beginning of year 1,000 2,000 Cash and cash equivalents at end of year $ 1,999,000 $ 1,000 See accompanying notes. 30 I mpact BioMedical, Inc. and Subsidiaries Consolidated Statements of Changes in Stockholders’ Equity For the Years Ended December 31, Shares Amount Shares Amount Capital Deficit Equity Subsidiary Total Common Stock Preferred Stock Additional Paid-in Accumulated Total Impact Non- controlling Interest in Shares Amount Shares Amount Capital Deficit Equity Subsidiary Total Balance, December 31, 2022 70,496,041 $ 70,000 - $ - $ 38,113,000 $ ( 8,625,000 ) $ 29,558,000 3,111,000 $ 32,669,000 Conversion of common stock to preferred stock ( 60,496,041 ) ( 60,000 ) 60,496,041 60,000 - - - - - Net loss - - - - - ( 4,336,000 ) ( 4,336,000 ) ( 71,000 ) ( 4,407,000 ) Balance, December 31, 2023 10,000,000 $ 10,000 60,496,041 $ 60,000 $ 38,113,000 $ ( 12,961,000 ) $ 25,222,000 $ 3,040,000 $ 28,262,000 Balance, December 31, 2023 10,000,000 $ 10,000 60,496,041 $ 60,000 $ 38,113,000 $ ( 12,961,000 ) $ 25,222,000 $ 3,040,000 $ 28,262,000 Balance 10,000,000 $ 10,000 60,496,041 $ 60,000 $ 38,113,000 $ ( 12,961,000 ) $ 25,222,000 $ 3,040,000 $ 28,262,000 Issuance of common stock, net of expenses 1,500,000 1,000 - - 3,725,000 - 3,726,000 - 3,726,000 Fractional shares as a result of reverse stock split 3,955 - - - - - - - - Stock based payments - - - - 19,000 - 19,000 - 19,000 Net (loss) income - - - - - ( 24,708,000 ) ( 24,708,000 ) ( 62,000 ) ( 24,770,000 ) Balance, December 31, 2024 11,503,955 $ 11,000 60,496,041 $ 60,000 $ 41,857,000 $ ( 37,669,000 ) $ 4,259,000 $ 2,978,000 $ 7,237,000 Balance 11,503,955 $ 11,000 60,496,041 $ 60,000 $ 41,857,000 $ ( 37,669,000 ) $ 4,259,000 $ 2,978,000 $ 7,237,000 See accompanying notes. 31 Impact BioMedical Inc and Subsidiaries NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. DESCRIPTION OF BUSINESS By leveraging technology and new science with strategic partnerships, we provide advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases. In addition to our existing efforts, we continually search for, and evaluate, other potential new offerings to add to our portfolio. Our business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBO technologies in exchange for milestone, and royalty payments. Currently, our operations are conducted, and our assets are owned through our principal subsidiaries: (i) Global BioLife, Inc. (“Global BioLife”), which was incorporated on April 14, 2017, (ii) Impact BioLife Science, Inc. (“Impact BioLife”), which was incorporated on August 28, 2020, (iii) Global BioMedical, Inc. (“Global BioMedical”), which was incorporated on April 18, 2017, and (iv) Sweet Sense, Inc. (“Sweet Sense”), which was incorporated on April 30, 2018. Linebacker Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Polyphenols are substances found in many nuts, vegetables, and berries. Linebacker compounds are modified Myricetin, which is a common plant-derived flavonoid. Myricetin exhibits a wide range of activities that include strong antioxidant and anti-inflammatory activities (source: NIH). Linebacker can potentially be developed as monotherapy or co-therapy to down-regulate PIM (proviral integration site for Moloney murine leukemia virus) kinase which plays a key role as an oncogene in various cancers (e.g. colon, lung, prostate, breast). Additional potential applications include inflammatory disorders and neurology. Linebacker-1 and Linebacker-2 compounds have been licensed to ProPhase Laboratories (NASDAQ: PRPH) for development and commercialization worldwide, from which Impact Biomedical could receive future milestone and royalty payments. Laetose Laetose™ technology demonstrates compelling potential in reducing caloric intake and glycemic index in foods, while also inhibiting tumor necrosis factor alpha (TNF-α), a cytokine associated with inflammatory chronic diseases (data on file with IBO). The patented formulation has potential to inhibit the inflammatory and metabolic response of sugar alone and has potential applications in therapeutic administration to reduce or limit inflammatory or metabolic diseases (e.g., diabetes). Use of Laetose in a daily diet, compared to sugar, could result in 30% lower sugar consumption and lower caloric and glycemic index/load. Functional Fragrance Formulation (“3F”) 3F is a suite of “functional fragrances” containing specialized botanical ingredients (e.g., terpenes) with potential application as an antimicrobial, or as an additive in insect repellents, detergents, lotions, shampoo, fabrics and other substances to increase effectiveness. Global BioLife is seeking to commercialize this product. Together with Chemia, we are attempting to license 3F. Any potential profits from the 3F project will be split between Global BioLife and Chemia pursuant to the terms of the 20- year Royalty Agreement. Equivir Equivir/Equivir G technology is a novel blend of FDA Generally Recognized as Safe (GRAS) eligible polyphenols (e.g. Myricetin, Hesperetin, Piperine) which have demonstrated antiviral effects with additional potential application as health supplements or medication. Polyphenols are substances found in many nuts, vegetables, and berries. Myricetin is a member of the flavonoid class of polyphenolic compounds with antioxidant properties. Hesperitin is a flavanone and Piperine is an alkaloid, commonly found in black pepper. Equivir/Equivir G is licensed to ProPhase Laboratories for development and commercialization worldwide 32 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation – The Company’s consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include all accounts of the Company and its majority owned and controlled subsidiaries. The Company consolidates entities in which it owns more than 50 % of the voting common stock and controls operations. All intercompany transactions and balances among consolidated subsidiaries have been eliminated. Non–controlling interest represents the minority equity investment in the Company’s subsidiaries, plus the minority investors’ share of the net operating results and other components of equity relating to the non–controlling interest. The consolidated financial statements include all accounts of the entities as of the reporting period ending dates and for the reporting periods as follows: SCHEDULE OF CONSOLIDATED FINANCIAL STATEMENTS INCLUDE ENTITIES REPORTING PERIOD AND ATTRIBUTABLE INTEREST Name of consolidated subsidiary State or other jurisdiction of incorporation or organization Date of incorporation or formation Attributable interest as of December 31, 2024 Attributable interest as of December 31, 2023 Global BioMedical, Inc. Nevada April 18, 2017 90.9 % 90.9 % Global BioLife, Inc. Nevada April 14, 2017 81.8 % 81.8 % BioLife Sugar, Inc Nevada April 23, 2018 90.9 % 90.9 % Happy Sugar Inc Nevada August 17, 2018 81.8 % 81.8 % Sweet Sense Inc. Nevada April 30, 2018 95.5 % 95.5 % Global Sugar Solutions Inc. Nevada November 7, 2019 100 % 100 % As of December 31, 2024, and December 31, 2023, the aggregate noncontrolling interest was equity of $ 2,978,000 and $ 3,040,000 , respectively, which are separately disclosed on the Consolidated Balance Sheets. Use of Estimates – The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the dates of the balance sheets and reported amounts of revenues and expenses during the reporting periods. Actual results could differ from these estimates. Reclassifications - Costs associated with Professional fees for the years ended December 31, 2024, and 2023 have been reclassified to Research and development to conform with current period presentation. For the year ended December 31, 2023, Sales and marketing costs have been reclassified from Other operating costs to Sales and marketing to conform with current period presentation. Earnings (Loss) per Share - Basic earnings (loss) per share is computed by dividing the net income (loss) attributable to the common stockholders by weighted average number of shares of common stock outstanding during the period. Fully diluted earnings (loss) per share is computed like basic income (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Dilutive financial instruments issued or outstanding for the years ended December 31, 2024 include 60,496,041 shares of Series A Convertible Preferred Shares which are not eligible for conversion until April 10, 2027, 880,000 options priced at $ 3.00 per share expiring on October 31, 2031 and 75,000 warrants priced at $ 3.75 per share expiring on June 13, 2025 . There were no dilutive financial instruments issued or outstanding for the year ended December 31, 2023. Fair Value of Financial Instruments – Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Fair Value Measurement Topic of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: ● Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets. ● Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and ● Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts reported in the balance sheet of cash, other receivables, accounts payable and accrued expenses approximate fair value because of the immediate or short-term maturity of these financial instruments. The fair value of notes receivable approximates their carrying value as the stated or discounted rates of the notes do reflect recent market conditions. Notes payable, related party are recorded at fair value based on several factors (see Note 9). 33 Notes receivable, unearned interest, and related recognition – The Company records all future payments of principal and interest on notes as notes receivable, which are then offset by the amount of any related unearned interest income. For financial statement purposes, the Company reports the net investment in the notes receivable on the consolidated balance sheet as current or long-term based on the maturity date of the underlying notes. Such net investment is comprised of the amount advanced on the loans, adjusting for net deferred loan fees or costs incurred at origination, amounts allocated to warrants received upon origination, and any payments received in advance, if applicable. The unearned interest is recognized over the term of the notes and the income portion of each note payment is calculated so as to generate a constant rate of return on the net balance outstanding. Net deferred loan fees or costs, together with discounts recognized in connection with warrants acquired at origination, are accreted as an adjustment to yield over the term of the loan. Recent Accounting Standards - The Financial Accounting Standards Board (FASB) issues various Accounting Standards Updates relating to the treatment and recording of certain accounting transactions. There are several new accounting pronouncements issued by FASB which are not yet effective. Each of these pronouncements, as applicable, has been or will be adopted by the Company. As of December 31, 2024, none of these pronouncements is expected to have a material effect on the financial position, results of operations or cash flows of the Company. In November 2023, the Financial Accounting Standards Board (“FASB”), issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which improves reportable segment disclosure through enhanced disclosures about significant segment expenses. The amendment is effective for fiscal years beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024 and early adoption is permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company has adopted the enhanced segment disclosures of the year ended December 31, 2024. The Company reports its segment information to reflect the manner in which the Company’s chief operating decision maker (“CODM”) reviews and assesses performance. The Company’s Chief Executive Officer and Chief Operating Officer have joint responsibilities as the CODM and review and assess the performance of the Company as a whole. The primary financial measures used by the CODM to evaluate performance and allocate resources are net income (loss) and operating income (loss). The CODM uses net income (loss) and operating income (loss) to evaluate the performance of the Company’s ongoing operations and as part of the Company’s internal planning and forecasting processes. Information on Net income (loss) and Operating income (loss) is disclosed in the Consolidated Statements of Operations. Segment expenses and other segment items are provided to the CODM on the same basis as disclosed in the Consolidated Statements of Operations. The CODM does not evaluate performance or allocate resources based on segment assets, and therefore such information is not presented in the notes to the financial statements In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures” which is intended to simplify various aspects related to accounting for income taxes. ASU 2023-09 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The amendments in ASU 2023-09 are effective for public business entities for fiscal years beginning after December 15, 2024, including interim periods therein. Early adoption of the standard is permitted, including adoption in interim or annual periods for which financial statements have not yet been issued. The Company is currently evaluating this ASU, but does not expect it to have material impact to its financial statements. In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Disaggregation of Income Statement Expenses (“DISE”) . ASU 2024-03 requires disaggregated disclosure of income statement expenses for public business entities. ASU 2024-03 does not change the expense captions an entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures within the footnotes to the financial statements. As revised by ASU No. 2025-01, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures, the provisions of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. With the exception of expanding disclosures to include more granular income statement expense categories, we do not expect the adoption of ASU 2024-03 to have a material effect on our consolidated financial statements taken as a whole. Property, Plant and Equipment – Property, plant and equipment are recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives or lease period of the assets whichever is shorter. Expenditures for renewals and betterments are capitalized. Expenditures for minor items, repairs and maintenance are charged to operations as incurred. Any gain or loss upon sale or retirement due to obsolescence is reflected in the operating results in the period the event takes place. Research and Development - Research and development costs are expensed as incurred. Total research and development costs were $ 555,000 for the year ended December 31, 2024, and $ 1,685,000 for year ended December 31, 2023. 34 Goodwill – Goodwill is the excess of cost of an acquired entity over the fair value of amounts assigned to assets acquired and liabilities assumed in a business combination. Goodwill is subject to impairment testing at least annually and will be tested for impairment between annual tests, which takes place during the fourth quarter, if an event occurs or circumstances change that would indicate the carrying amount may be impaired. FASB ASC Topic 350 provides an entity with the option to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Some of the qualitative factors considered in applying this test include consideration of macroeconomic conditions, industry and market conditions, cost factors affecting the business, and overall financial performance of the business. If, after completing the assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company will proceed to a quantitative test. If qualitative factors are not deemed sufficient to conclude that the fair value of the reporting unit more likely than not exceeds its carrying value, then a one-step approach is applied in making an evaluation. The evaluation utilizes an income approach (discounted cash flow analysis). The computations require management to make significant estimates and assumptions, including, among other things, selection of comparable publicly traded companies, the discount rate applied to future earnings reflecting a weighted average cost of capital, and earnings growth assumptions. The Company believes the estimates and assumptions used in our impairment assessments are reasonable and based on available market information, but variations in any of the assumptions could result in materially different calculations of fair value and determinations of whether or not an impairment is indicated. A discounted cash flow analysis requires management to make various assumptions about future sales, operating margins, capital expenditures, working capital, and growth rates. Cash flow projections are derived from one-year budgeted amounts plus an estimate of later period cash flows, all of which are determined by management. Subsequent period cash flows are developed for each reporting unit using growth rates that management believes are reasonably likely to occur. Impairment of goodwill is measured as the excess of the carrying amount of goodwill over the fair values of recognized and unrecognized assets and liabilities of the reporting unit. As of December 31, 2024, the Company fully impaired goodwill. No impairment was recognized during the year ended December 31, 2023. (Note 7) Intangible Assets - The estimated fair values of acquired intangibles are generally determined based upon future economic benefits such as earnings and cash flows. Acquired identifiable intangible assets are recorded at fair value and are amortized over their estimated useful lives. Acquired intangible assets with an indefinite life are not amortized but are reviewed for impairment at least annually as of December 31 st , or more frequently whenever events or changes in circumstances indicate that the carrying amounts of those assets are below their estimated fair values. Impairment is tested under ASC 350. No impairment was recognized as of year ended December 31, 2024 or the year ended December 31, 2023. (Note 9). Recoverability of Long-Lived Assets - We evaluate long-lived assets such as property, equipment and definite lived intangible assets, such as patents, for impairment whenever events or circumstances indicate that the carrying value of the assets recognized in our financial statements may not be recoverable. Factors that we consider include whether there has been a significant decrease in the market value of an asset, a significant change in the way an asset is being utilized, or a significant change, delay or departure in our strategy for that asset, or a significant change in the macroeconomic environment, such as the impact of the COVID-19 pandemic. Our assessment of the recoverability of long-lived assets involves significant judgment and estimation. These assessments reflect our assumptions, which, we believe, are consistent with the assumptions hypothetical marketplace participants use. Factors that we must estimate when performing recoverability and impairment tests include, among others, forecasted revenue, margin costs and the economic life of the asset. If impairment is indicated, we determine if the total estimated future cash flows on an undiscounted basis are less than the carrying amounts of the asset or assets. If so, an impairment loss is measured and recognized. Our impairment loss calculations require that we apply judgment in identifying asset groups, estimating future cash flows, determining asset fair values, and estimating asset’s useful lives. The Company reviews identifiable amortizable intangible assets for impairment whenever events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. Determination of recoverability is based on the lowest level of identifiable estimated undiscounted cash flows resulting from use of the asset and its eventual disposition. Measurement of any impairment loss is based on the excess of the carrying value of the asset over its fair value. Based on the uncertainty of forecasts inherent with a new product, events such as the failure to generate forecasted revenue from new products could result in a non-cash impairment in future periods. Revenue - The Company has adopted ASC Topic 606 , Revenue from Contracts with Customers (“Topic 606”). The Company enters into licensing and development agreements with collaborators for the development of its technologies. The terms of these agreements contain multiple performance obligations which may include (i) licenses, or options to obtain licenses, to the Company’s technology, (ii) rights to future technological improvements, and/or (iii) research activities to be performed on behalf of the collaborative partner, Payments to the Company under these agreements may include upfront fees, option fees, exercise fees, payments based upon the achievement of certain milestones, and royalties on product sales. Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under the agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when or as the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration to which it is entitled in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when or as the performance obligation is satisfied. Provision for Credit Losses - The Company adopted amended accounting guidance ASC Topic 326 which requires an allowance for credit losses to be deducted from the amortized cost basis of financial assets to present the net carrying value at the amount that is expected to be collected over the contractual term of the asset considering relevant information about past events, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In estimating expected losses in the loan and lease portfolio, borrower-specific financial data and macro-economic assumptions are utilized to project losses over a reasonable and supportable forecast period. Assumptions and judgment are applied to measure amounts and timing of expected future cash flows, collateral values and other factors used to determine the borrowers’ abilities to repay obligations. After the forecast period, the Company utilizes longer-term historical loss experience to estimate losses over the remaining contractual life of the loans. As of December 31, 2024 and 2023 the Company has deemed that no reserve on credit losses were necessary. Continuing Operations and Going Concern - The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of our assets and the satisfaction of liabilities in the normal course of business. As reflected in the accompanying financial statements the Company has incurred operating losses as well as negative cash flows from operating activities over the past two years. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued. These consolidated financial statements do not include any adjustments to the specific amounts and classifications of assets and liabilities, which might be necessary should we be unable to continue as a going concern. To continue as a going concern, the Company completed an initial public offering on September 16, 2024 raising $ 3,726,000 net of issuance costs and is currently listed on the NYSE American under the ticker symbol IBO. Although there is no certainty that management plans will be able to satisfy the requirements to continue operating as a going concern, management intends to take additional actions necessary to continue as a going concern. Management’s plans concerning these matters include, among other things, monetization of its intellectual properties, and tightly controlling operating costs. 35 3. Financial Instruments Cash, Note payable, related party The following tables show the Company’s cash, cash equivalents, and note payable, related party by significant investment category as of: Schedule of Cash, Cash Equivalents, Restricted Cash, and Note Payable Related Party by Significant Investment Category 2024 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Note Payable, Related Party Level 1 Cash $ 1,999,000 $ - $ 1,999,000 $ 1,999,000 $ - Level 2 Note payable, related party 13,946,000 ( 5,068,000 ) 8,878,000 - 8,878,000 Total $ 15,945,000 $ ( 5,068,000 ) $ 10,877,000 $ 1,999,000 $ 8,878,000 2023 Adjusted Cost Unrealized Gain/(Loss) Fair Value Cash and Cash Equivalents Level 1 Cash $ 1,000 $ - $ 1,000 $ 1,000 Total $ 1,000 $ - $ 1,000 $ 1,000 4. Notes Receivable On February 19, 2021, Impact BioMedical, Inc, entered into a promissory note with an individual. The Company loaned the principal sum of $ 206,000 , with interest at a rate of 6.5 %, and maturity date of August 19, 2022 later amended to February 19, 2026. Monthly payments are due on the twenty-first day of each month and continuing each month thereafter until February 19, 2026. This note is secured by certain real property situated in Collier County, Florida. The outstanding principal and interest as of December 31, 2024 is approximately $ 201,000 with $ 184,000 classified in Current portion of notes receivable and $ 17,000 classified as Notes receivable on the accompanying consolidated balance sheet. The outstanding principal and interest as of December 31, 2023, approximately $ 203,000 and is classified in current notes receivable on the accompanying consolidated balance sheet. 5. Prepaid Expenses and other current assets Prepaid expenses at December 31, 2024 of $ 265,000 driven by $ 263,000 of prepaid insurance. There were no prepaid expenses for year ended December 31, 2023 6. Property, Plant and Equipment, Net Property, plant and equipment consisted of the following as of: Schedule of Property, Plant and Equipment Estimated December 31, December 31, Useful Life 2024 2023 Machinery and equipment 5 - 10 years $ 30,000 $ 25,000 Construction in progress - 263,000 Total Cost 30,000 293,000 Less accumulated depreciation 13,000 6,000 Property, plant and equipment, net $ 17,000 $ 287,000 Depreciation expense for the years ended December 31, 2024 and 2023 were approximately $ 7,000 and $ 6,000 , respectively. 7. Goodwill Goodwill balances and activity for the year ended December 31, 2024 and year ended December 31, 2023 consisted of the following: Schedule of Goodwill Balance at December 31, 2023 $ 25,093,000 Goodwill adjustment ( 25,093,000 ) Balance at December 31, 2024 $ - As of December 31, 2024, management performed annual goodwill impairment testing., A quantitative analysis was prepared utilizing the Market Approach and Income Approach valuing the Company and an impairment of goodwill was identified as result of these tests. For the year ended December 31, 2023, management performed annual goodwill impairment testing and no impairment was deemed necessary. The guideline public company Market Approach produced a mean business enterprise value indication using estimated 2026 results of $ 49.8 million. The Income Approach was based upon the use of a discounted pro forma cash flow model and produced a business enterprise value indication of $ 44.9 million. A weighting of 30 % to the weighted value indicated was applied under the Market Approach, and a weighting of 70 % to the value indicated under the Income Approach. A lower weighting was applied to the Market Approach due to the fact of using forecasted earnings of the Company. Based upon the above weightings, an initial value of $ 46.4 million for Impact was calculated. Adding cash of $ 201,000 to the initial business enterprise value produced a concluded business enterprise value of $ 46.6 million (rounded) for Impact. Subtracting interest-bearing debt of $ 11.9 million, results in a Fair Value for the common equity of Impact of $ 34.7 million. As of September 30, 2023, the indicated equity value exceeded the carrying amount by approximately $ 5.1 million or 14.7 %. 36 8. Intangible Assets The definite-lived intangible assets, to be amortized over 20 years, balances, and activity for the year ended December 31, 2024 and year ended December 31, 2023 consisted of the following: Schedule of Intangible Assets 2024 2023 Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Gross Carrying Amount Accumulated Amortization Net Carrying Amount Developed technology assets 20 years $ 22,260,000 $ 4,452,000 $ 17,808,000 $ 22,260,000 $ 3,339,000 $ 18,921,000 $ 22,260,000 $ 4,452,000 $ 17,808,000 $ 22,260,000 $ 3,339,000 $ 18,921,000 The following table represents future amortization of developed technologies for the years ending December 31: Schedule of Future Amortization of Developed Technologies 2025 $ 1,113,000 2026 $ 1,113,000 2027 $ 1,113,000 2028 $ 1,113,000 2029 $ 1,113,000 Thereafter $ 12,243,000 9. NOTE PAYABLE, RELATED PARTY On December 31, 2020, and later amended, the Company executed a Revolving Promissory Note (“Note”) with DSS, a related party, which accrues interest at a rate of 4.25 % and is due in full at the maturity date of September 30, 2030 . The Note was further amended on July 24, 2024 with an effective date of September 16, 2024 to i) allow the Company to pay certain principal and/or interest payments owing under the repayment terms in an exchange for potential of equity in the Company, ii) change the quarterly interest due dates to the last day of each calendar quarter (i.e. December 31, March 31, June 30 and September 30), iii) to adjust the On Demand feature so that it starts after the 24th month, iv) continue the planned repayment program commencing on the 37th month and on the last day of each month thereafter through August 31, 2030 to pay a fixed monthly payment of $ 126,381 , v) to continue the scheduled maturity date of September 30, 2030, and vi) adjusts the interest rate to be the WSJ Prime Rate plus 0.50 %. This Note is secured by the assets of the Company. As of December 31, 2024 and December 31, 2023 the outstanding balance, inclusive of interest was $ 8,878,000 (net of change in fair value of the Note of $ 5,068,000 ) and $ 12,074,000 , respectively. The $ 8,878,000 is recorded in Note payable, related party at December 31, 2024. The $ 12,074,000 at December 31, 2023 is included in Current portion of note payable, related party. The Company accounts for this Note as a liability under ASC 480, Distinguishing Liabilities form Equity (“ASC 480”). In accordance with ASC 825-10, the carrying value of the Note will be recorded at fair value and will be remeasured at each reporting period with the changes in fair value recognized in earnings. We considered various valuation methodologies in our analysis of the embedded derivative. Valuation methodologies can generally be aggregated into the following three approaches: the Market Approach, the Income Approach, and the Cost Approach. Based on our analysis of the facts and circumstances, in estimating the fair value of the Note payable, related party, we utilized a discounted cash flow method (income approach), in the form of a Monte Carlo simulation of the Company’s stock price and volume weighted average price (“VWAP”) throughout 36-month period from the Effective Date relative to its closing stock price and VWAP as of the Valuation Date, or $2.00 and $2.38, respectively. The simulated analysis estimates the expected note cash flow from the date the first payment is due and until the equity conversion rights expire under the terms of the Note payable, related party based on the following steps: 1) Developed the Note Payable repayment schedule 2) Developed the following inputs underlying the simulation analysis i) Stock price ii) VWAP 3) Inputs (i) and (ii), were assigned a normal probability distribution, which has a mean of 0 and a standard deviation of 1, and a correlation of .9885 based on analysis of the guideline public companies 4) Ran a simulation with 25,000 trials for purposes of capturing the key inputs discussed above (i.e., forecasting the stock price and VWAP). 5) For the period from the 37th payment to maturity date, the DCF Method includes the remaining payments required to be made in cash. 6) Captured the results of the simulation and concluded based on the simulation results 10. STOCKHOLDERS’ EQUITY On May 10, 2023, the Company’s Board of Directors approved an amendment to the Articles of Incorporation of the Company to increase the total number of shares of Common Stock to 4,000,000,000 shares with a par value of $ 0.001 . Each share of Common Stock when issued, shall have one (1) vote on all matters presented to the stockholders. Our Amended and Restated Articles of Incorporation also authorized 100,000,000 shares of preferred stock, par value $ 0.001 per share. On May 11, 2023, the Company effected a forward split. As a result, there were 3,877,282,251 shares of our Common Stock and no shares of preferred stock issued and outstanding. Prior to the split, there were 125,073,621 shares of our Common Stock and no shares of preferred stock issued and outstanding. On October 31, 2023, the Company effected a reverse stock split of 1 for 55 . Also on October 31, 2023, DSS BioHealth Securities, Inc., the Company’s largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing its ownership of the Company’s Common Stock from approximately 88% to approximately 12%. As of December 31, 2023, there were 10,000,000 shares of our Common Stock and 60,496,041 shares of preferred stock issued and outstanding. On August 8, 2023 DSS, the Company’s largest shareholder, distributed to its shareholders of record on July 10, 2023 4 shares of Impact Bio’s stock for 1 share they owned. Each share of Impact BioMedical distributed as part of the distribution will not be eligible for resale until 180 days from the date Impact BioMedical’s initial public offering becomes effective under the Securities Act, subject to the discretion of the Company to lift the restriction sooner. On October 31, 2023, the Company effected a reverse stock split of 1 for 55 . As of December 31, 2023 there were 3,877,282,251 shares of our Common Stock issued and outstanding which was converted to 70,496,041 shares. Also on October 31, 2023, DSS BioHealth Securities, Inc., the Company’s largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing its ownership of the Company’s Common Stock from approximately 88% to approximately 12%. The Series A Convertible Preferred Shares are not eligible for conversion until April 10, 2027. 37 On September 16, 2024, Impact Biomedical Inc., entered into an underwriting agreement (the “Underwriting Agreement”) with Revere Securities, LLC., as representative (the “Representative”) of the underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to sell to the Underwriters in a firm commitment initial public offering (the “Offering”) an aggregate of 1,500,000 of the Company’s shares of common stock, par value $ 0.001 per share at a public offering price of $ 3.00 per share. On September 17, 2024, the Company closed the Offering. The total net proceeds to the Company from the Offering, after deducting discounts, expenses allowance and expenses, was approximately $ 3,726,000 . A final prospectus relating to this Offering was filed with the Commission on September 16, 2024. The shares of Common Stock were approved to list on the NYSE American under the symbol “IBO” and began trading there on September 16, 2024. The Company also issued warrants to the Representative and its affiliates (the “Representative’s Warrants”) warrants to purchase the number of shares of Common Stock in the aggregate equal to 5 % of the Common Stock to be issued and sold in this offering (including any Shares of Common Stock sold upon exercise of the over-allotment option, if applicable). The Representative’s Warrants are exercisable for a price per share equal to 125 % of the public offering price. The warrants are exercisable at any time, in whole or in part, commencing nine (9) months from the date of commencement of sales of the offering and ending on the third anniversary thereof. As of September 30, 2024, the Representative had not exercised any of these warrants. As of September 30, 2024, only the 1,500,000 shares included in the Offering are freely tradable on the NYSE. The remaining 9,997,703 are restricted from trading for 180 days from the Offering date. Equity Incentive Plan – During 2023, the Company’s shareholders adopted the 2023 Employee, Director and Consultant Equity Incentive Plan (the “2023 Plan”). The 2023 Plan provides for the issuance of an initial 18,762,000 shares of common stock authorized to be issued for grants of options, restricted stock and other forms of equity to employees, directors and consultants. In addition, on the first day of each calendar year, for a period of not more than ten (10) years, commencing January 1, 2025, or the first business day of the calendar year if the first day of the calendar year falls on a Saturday or Sunday, the shares available under this plan will automatically increase in an amount equal to the lesser of (i) two percent (2%) of the total number of shares of Common Stock outstanding as of December 31 of the preceding fiscal year or (ii) such number of shares of Common Stock as determined by the Board of Directors. Under the terms of the 2023 Plan, options granted thereunder may be designated as options which qualify for incentive stock option treatment (“ISOs”) under Section 422A of the Internal Revenue Code, or options which do not qualify (“NQSOs”). As of December 31, 2024, there are 18,037,079 shares available under this plan. Stock-Based Compensation – The Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors and consultants. Such awards include option grants, warrant grants, and restricted stock awards. On October 1, 2024, 880,000 option grants with a purchase price of $ 3.00 per share were awarded to certain officers, directors and consultants of the Company. These options have various vesting periods, and all expire on October 31, 2031. Potential proceeds of these grants is $ 2,640,000 and are fair valued using a Black-Scholes model at approximately $ 50,000 . The Company record stock based compensation expense of approximately $ 19,000 for the year ended December 31, 2024 and is included in Sales, general and administrative compensation (inclusive of stock based compensation) on the accompanying Statement of Operations. There were no stock-based payments made during the twelve months ended December 31, 2023. 11. INCOME TAXES The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial reporting and tax basis of assets and liabilities. Deferred tax assets are reduced, if deemed necessary, by a valuation allowance for the amount of tax benefits which are not expected to be realized. The components of income tax benefit for the years ended December 31, 2024, and 2023 are as follows: SCHEDULE OF COMPONENTS OF INCOME TAX BENEFIT Income Tax Expense (Benefit) Year Ended December 31, 2024 Year Ended December 31, 2023 Current tax payable Federal $- $- State - - Total current tax payable - - Deferred tax Federal 30,000 ( 920,000 ) State 3,000 ( 94,000 ) Total deferred tax $ 33,000 $ ( 1,014,000 ) Less increase in valuation allowance - 1,014,000 Total income tax expense $ 33,000 $ - Individual components of deferred tax assets and liabilities are approximately as follows: SCHEDULE OF DEFERRED TAX ASSETS AND LIABILITIES Deferred Tax Assets & Liabilities: Deferred Tax assets: Impairment of investment $ 929,000 $ 929,000 Research & development cost 519,000 538,000 Compensation 18,000 - Net Operating loss 2,950,000 2,087,000 Gross deferred tax assets 4,416,000 3,554,000 Deferred tax liability: Note payable, related party FMV adjustment ( 1,148,000 ) - Intangible assets ( 3,912,000 ) ( 4,164,000 ) Gross deferred tax liability ( 5,060,000 ) ( 4,164,000 ) Less valuation allowance ( 2,625,000 ) ( 2,625,000 ) Net deferred tax liability $ ( 3,269,000 ) $ ( 3,235,000 ) SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2024 2023 Statutory United States federal rate 21.0 % 21.0 % State income taxes net of federal benefit 0 % 1.7 % Change in valuation allowance 0 % ( 22.7 )% Effective rate 21.0 % 0.0 % As of December 31, 2024, and 2023, the Company has net operating loss carry forwards of approximately $ 13,020,000 and $ 9,209,000 respectively. The Company does not have other temporary differences associated with the amortization of intangible assets. As of December 31, 2024, and 2023, the total deferred tax assets carry-forward were $ 4,416,000 and $ 3,554,000 , respectively. The deferred tax assets could be carried forward indefinitely. The full utilization of the deferred tax assets in the future is dependent upon the Company’s ability to generate taxable income. Considering the development stage of the Company, management believed that it was probable that the Company would not use tax assets in the near future. Accordingly, a valuation allowance of an equal amount has been established. The Company recognizes interest accrued and penalties related to unrecognized tax benefits in tax expense. During the years ended December 31, 2023 and 2022 the Company recognized no interest and penalties. 38 12. COMMITMENTS AND CONTINGENCIES On August 15, 2018, the Company entered into Royalty Agreement with Chemia Corporation (“Chemia”) pursuant to which Chemia transferred to the Company all of its right to 3F (Functional Fragrance Formulation). This agreement has a 20-year term and auto renews for a period of 1 year unless mutually agreed upon by both parties. 3F consists of 3F Mosquito Repellant and 3F Anti-Viral formulations. Based on the Royalty Agreement, the Company should cover all the costs to prepare and finalize necessary patent application and other intellectual property related to 3F. Chemia agreed to support the Company in efforts leading to development of 3F intellectual property and it is licensing. Based on Royalty Agreement any payments received from development, sales, licensing or transfer of 3F technology will be paid 50 % to the Company and 50 % to Chemia. On November 27, 2018, Company and Chemia signed an Addendum to Royalty Agreement (“Addendum”), according to which the Company granted Chemia a royalty-based limited license for purposes of making and selling fragrances embodying the 3F technology. Based on the Addendum, Chemia should pay the Company 5 % of net sales in royalty. On November 8, 2019, both companies entered into Amendment no.1 to Royalty Agreement, based on which certain expenses borne by the Company towards patent application and licensing should be reimbursed to the Company before any royalty payments are made. For the years ended December 31, 2024 and 2023, there were no reimbursements or royalties paid to the Company and the Company cannot be assured that Chemia’s efforts will end up in any future sales of the technology. On February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (“Global”), and Impact BioLife Sciences, Inc. (“BioLife Sciences”), and GRDG entered into a Licensing Proceeds Distribution Agreement (“GRDG Agreement”), whereas GRDG would transfer its 20 % equity position in both Global and BioLife Sciences to the Company in exchange for 20 % interest in Global and/or BioLife Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third Party, net of specific costs. This Licensing Agreement ended in September 2023 as core technologies achieved significant development milestones. On March 19, 2022, Impact BioMedical entered into a License Agreement (“Equivir License”) with a third-party (“Licensee”) where the Licensor is granted the right, amongst other things, to develop, commercialize, and sell the Company’s Equivir technology. In exchange, the Licensee shall pay the Company a royalty of 5.5 % of net sales. Under the terms of the Equivir Agreement, the Company shall reimburse the Licensee for 50 % of the development costs provided that the development costs shall not exceed $ 1,250,000 . As of December 31, 2024 and December 31, 2023, $ 200,000 , and $ 200,000 , respectively, have been recorded in relation to the Equivir License as development of the Equivir technology. Employment Agreements – Impact BioMedical has an employment agreement with it CEO Frank Heuszel in which Mr. Heuszel’s agreement contains a mandatory bonus clause of $ 150,000 for the first year of the employment term, $ 100,000 for the second year of the employment term, and $ 100,000 for the third year of the employment term. As of December 31, 2024, approximately $ 38,000 is accrued for year one of Mr. Heuszel’s bonus. Contingent Litigation Payments – The Company retains the services of professional service providers, including law firms that specialize in intellectual property licensing, enforcement and patent law. These service providers are often retained on an hourly, monthly, project, contingent or a blended fee basis. In contingency fee arrangements, a portion of the legal fee is based on predetermined milestones or the Company’s actual collection of funds. The Company accrues contingent fees when it is probable that the milestones will be achieved, and the fees can be reasonably estimated. As of December 31, 2024, the Company had no t accrued any contingent legal fees pursuant to these arrangements. Contingent Payments – The Company is not party to any agreements with funding partners who have rights to portions of intellectual property monetization proceeds that the Company receives. 39 13. Related Party Transactions Research and Development Activities Based on Shareholders Agreement entered into on April 26, 2017, the Company would fund the scientific operations of GRDG, a company involved in research and development of biomedical products which is a minority stockholder of two of the Company’s subsidiaries and is owned by Daryl Thompson, a director of many subsidiaries of the Company, to do the development and research works on the biomedical products for the Company. On February 15, 2022, the Company and its subsidiaries, Global BioLife, Inc. (“Global”), and Impact BioLife Sciences, Inc. (“BioLife Sciences”), and GRDG entered into a Licensing Proceeds Distribution Agreement (“GRDG Agreement”), whereas GRDG would transfer its 20 % equity position in both Global and BioLife Sciences to the Company in exchange for 20 % interest in Global and/or BioLife Science revenue received from the exclusive or non-exclusive licensing of and/or the sale of Global Intellectual Property to a Third Party, net of specific costs. As of the date of this report, no contingent liability has been recognized under the GRDG Agreement. As of December 31, 2024 and 2023, the Company incurred approximately $ 25,000 and $ 447,000 , respectively, in expenses. General and Administrative Costs There are certain general and administrative costs incurred by DSS, a related party, on behalf of the Company which are passed through to the Company on a monthly basis. These costs consist of primarily payroll costs for certain DSS employees and are allocated based on estimated time spent on behalf of the Company. Beginning in January 2024 and through September 2024, these costs are approximately $ 31,000 per month. Beginning October 2024, these costs are approximately $ 26,000 per month. As of December 31, 2024, the Company incurred $ 357,000 in related expenses. As of December 31, 2023, the Company incurred approximately $ 144,000 in related expenses. Note payable, related party On December 31, 2020, and later amended, the Company executed a Revolving Promissory Note (“Note”) with DSS, a related party, which accrues interest at a rate of 4.25 % and is due in full at the maturity date of September 30, 2030 . The Note was further amended on July 24, 2024 with an effective date of September 16, 2024 to i) allow the Company to pay certain principal and/or interest payments owing under the repayment terms in an exchange for potential of equity in the Company, ii) change the quarterly interest due dates to the last day of each calendar quarter (i.e. December 31, March 31, June 30 and September 30), iii) to adjust the On Demand feature so that it starts after the 24th month, iv) continue the planned repayment program commencing on the 37th month and on the last day of each month thereafter through August 31, 2030 to pay a fixed monthly payment of $ 126,381 , v) to continue the scheduled maturity date of September 30, 2030, and vi) adjusts the interest rate to be the WSJ Prime Rate plus 0.50 %. As of December 31, 2024 and December 31, 2023 the outstanding balance, inclusive of interest was $ 8,878,000 (net of change in fair value of the Note of $ 5,068,000 ) and $ 12,074,000 , respectively. The $ 8,878,000 is recorded in Note payable, related party at December 31, 2024. The $ 12,074,000 at December 31, 2023 is included in Current portion of note payable, related party. 14. SUBSEQUENT EVENTS The Company has evaluated all subsequent events and transactions through March 24, 2025, the date that the consolidated financial statements were available to be issued and noted no subsequent events requiring financial statement recognition or disclosure other than what was identified below: On February 25, 2025, the Company completed the acquisition of certain assets owned by DSS Pure Air, Inc. (“DSS PureAir”), a related party, for $ 1,150,000 to be paid by 545,024 shares of the Company’s common stock calculated on a 10 day VWAP. Assets acquired included inventory and intellectual property of the Celios air purification system. On February 26, 2025, the Company issued 36,433 shares of the Company’s common stock as payment of legal fees incurred associated with the Company’s IPO, registration of shares associated with its equity incentive plan as well as other related services. The Company and DSS have agreed to settle a portion of the outstanding indebtedness that Impact BioMedical owes to DSS under the Promissory Note in the amount of $ 8,697,142.80 through the issuance of 2,415,873 shares of the Company’s common stock, at a conversion ratio of $ 3.60 per share, which was equal to the closing market price of the Company’s common stock on March 24, 2025. 40 ITEM 9 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None